Home » Stocks » ARPO

Aerpio Pharmaceuticals, Inc. (ARPO)

Stock Price: $1.05 USD 0.00 (0.00%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $1.07 +0.02 (1.91%) May 7, 6:47 PM
Market Cap 49.68M
Revenue (ttm) 15.00M
Net Income (ttm) -4.32M
Shares Out 42.62M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $1.05
Previous Close $1.05
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.07
Day's Range 1.04 - 1.10
Day's Volume 593,114
52-Week Range 0.57 - 2.31

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Aerpio Pharmaceuticals (ARPO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

1 month ago - Zacks Investment Research

Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago - Zacks Investment Research

CINCINNATI, March 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 in ...

1 month ago - GlobeNewsWire

Quantum Leap Healthcare Collaborative-sponsored I-SPY COVID Trial will not further test Aerpio Pharmaceuticals Inc's (NASDAQ: ARPO) razuprotafib. Razuprotafib was chosen because it was believed to stabi...

2 months ago - Benzinga

SAN FRANCISCO and CINCINNATI, March 05, 2021 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio P...

2 months ago - GlobeNewsWire

Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

2 months ago - Zacks Investment Research

Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.

4 months ago - Zacks Investment Research

Aerpio Pharmaceuticals (ARPO) has been struggling lately, but the selling pressure may be coming to an end soon.

4 months ago - Zacks Investment Research

CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, tod...

4 months ago - GlobeNewsWire

Does Aerpio Pharmaceuticals, Inc. (ARPO) have what it takes to be a top stock pick for momentum investors? Let's find out.

4 months ago - Zacks Investment Research

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific upd...

Other stocks mentioned: ANPC, ARVN, SYBX, VERU
4 months ago - Benzinga

Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group.

4 months ago - GlobeNewsWire

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

Other stocks mentioned: RGEN, TCON
5 months ago - Zacks Investment Research

Aerpio Pharmaceuticals, Inc. (ARPO) Management on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Conference Call Today, November 10 , 2020 at 8:30 a.m. EST

5 months ago - GlobeNewsWire

CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disea...

6 months ago - GlobeNewsWire

Call Taking Place on Thursday, November 12th @ 11amET Call Taking Place on Thursday, November 12th @ 11amET

6 months ago - GlobeNewsWire

The trial in moderate-to-severe patients is Aerpio's second clinical trial in COVID-19 patients and is funded in part by the U . S . military

6 months ago - GlobeNewsWire

Topline Data Expected 4Q 2020 Topline Data Expected 4Q 2020

7 months ago - GlobeNewsWire

SAN FRANCISCO and CINCINNATI, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today dosing...

8 months ago - GlobeNewsWire

Aerpio Pharmaceuticals' (ARPO) Management on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Conference Call Today, August 12, 2020 at 8:30 a.m. EDT

8 months ago - GlobeNewsWire

CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular dis...

8 months ago - GlobeNewsWire

CINCINNATI, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through the Medical Technology Enterprise Consortium (MTEC) annou...

9 months ago - GlobeNewsWire

In the latest trading session, Aerpio Pharmaceuticals, Inc. (ARPO) closed at $1.26, marking a +1.61% move from the previous day.

10 months ago - Zacks Investment Research

Is (ARPO) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Aerpio Pharmaceuticals.

10 months ago - Zacks Investment Research

Aerpio Pharmaceuticals, Inc. (ARPO) closed the most recent trading day at $1.25, moving +0.81% from the previous trading session.

10 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for June 19th

Other stocks mentioned: DLTH
10 months ago - Zacks Investment Research

Is (ARPO) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the public health and safety concerns related to the novel coron...

11 months ago - GlobeNewsWire

CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular dis...

11 months ago - GlobeNewsWire

SAN FRANCISCO and CINCINNATI, May 27, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agree...

11 months ago - GlobeNewsWire

SAN FRANCISCO and CINCINNATI, May 27, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement h...

11 months ago - PRNewsWire

Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

11 months ago - Zacks Investment Research

Aerpio Received an Immediate Payment of $15 million Aerpio Received an Immediate Payment of $15 million

11 months ago - GlobeNewsWire

Aerpio Pharmaceuticals, Inc. (ARPO) closed at $0.72 in the latest trading session, marking a +0.61% move from the prior day.

1 year ago - Zacks Investment Research

Is (ARPO) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Aerpio Pharmaceuticals, Inc. (ARPO) on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Our year-end roundtable rolls into 2020 with a look at small-cap investing.

Other stocks mentioned: ALX, BWEL, PFIN, STAR, TPL, WSTL
1 year ago - Seeking Alpha

Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 years ago - Zacks Investment Research

Shares of Aerpio Pharmaceuticals Inc. plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopathy failed...

2 years ago - Market Watch

About ARPO

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hyp... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
ARPO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ARPO stock is "Buy." The 12-month stock price forecast is 1.75, which is an increase of 66.67% from the latest price.

Price Target
$1.75
(66.67% upside)
Analyst Consensus: Buy